Cargando…

Advances in therapeutic options for newly diagnosed, high-risk AML patients

Acute myeloid leukemia (AML) is an aggressive malignancy characterized by clonal proliferation of neoplastic immature precursor cells. AML impacts older adults and has a poor prognosis. Despite recent advances in treatment, AML is complex, with both genetic and epigenetic aberrations in the malignan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doucette, Kimberley, Karp, Judith, Lai, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111550/ https://www.ncbi.nlm.nih.gov/pubmed/33995985 http://dx.doi.org/10.1177/20406207211001138

Ejemplares similares

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities
por: Oshikawa, Gaku, et al.
Publicado: (2023)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
por: Uy, Geoffrey L., et al.
Publicado: (2022)

Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
por: Ricciardi, Luca, et al.
Publicado: (2022)

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review
por: Hao, Qiukui, et al.
Publicado: (2022)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

Recent drug approvals for acute myeloid leukemia
por: Lai, Catherine, et al.
Publicado: (2019)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

Advances in therapeutic options for portal hypertension
por: Vilaseca, Marina, et al.
Publicado: (2018)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
por: Li, Jun, et al.
Publicado: (2022)

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
por: Halpern, Anna B., et al.
Publicado: (2018)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
por: Vachhani, Pankit, et al.
Publicado: (2022)

New Therapeutic Options for Advanced Hepatocellular Carcinoma
por: Ma, Yu-Shui, et al.
Publicado: (2020)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A case of high‐risk AML in a patient with advanced systemic mastocytosis
por: Fazio, Manlio, et al.
Publicado: (2023)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

High-Dose Chemotherapy in Children with Newly Diagnosed Medulloblastoma
por: Lafay-Cousin, Lucie, et al.
Publicado: (2022)

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
por: Jia, Bei, et al.
Publicado: (2018)

Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic
por: Raman, Hari S., et al.
Publicado: (2021)

Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
por: Dermine, Solène, et al.
Publicado: (2019)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
por: Massironi, Sara, et al.
Publicado: (2020)

Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges
por: Ling, Yuan, et al.
Publicado: (2017)

Advances in the treatment of newly diagnosed primary central nervous system lymphomas
por: Qian, Liren, et al.
Publicado: (2017)

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE
por: Wang, Yuexi, et al.
Publicado: (2023)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2023)

Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature
por: Waqar, Mueez, et al.
Publicado: (2022)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
por: DiSilvestro, Paul, et al.
Publicado: (2021)

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
por: Stamm, Hauke, et al.
Publicado: (2018)

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
por: Hagen, Patrick, et al.
Publicado: (2022)

Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas
por: Carrete, Luis R., et al.
Publicado: (2022)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t7bkt1lqnh5vtr31glkvdnjk9k